Summary
Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd, is a life sciences company that develops and commercializes diagnostic and therapeutic products. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such as midkine ELISA kit, advangen international hair loss products and evolis products. Cellmid develops CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. The company markets its products in Australia and Japan. Cellmid is headquartered in Sydney, New South Wales, Australia.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Cellmid Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
- Cellmid Ltd Company Overview
Cellmid Ltd Company Snapshot Cellmid Ltd Pipeline Products and Ongoing Clinical Trials Overview Cellmid Ltd – Pipeline Analysis Overview Cellmid Ltd - Key Facts Cellmid Ltd - Major Products and Services Cellmid Ltd Pipeline Products by Development Stage Cellmid Ltd Pipeline Products Overview CK3000 Cancer Screening Test CK3000 Cancer Screening Test Product Overview Companion Diagnostic Assay - Glioblastoma Companion Diagnostic Assay - Glioblastoma Product Overview CS5000 Cancer Screening Test CS5000 Cancer Screening Test Product Overview MK Protein - Cancer MK Protein - Cancer Product Overview MK-ELISA Assay - Bile Duct Cancer MK-ELISA Assay - Bile Duct Cancer Product Overview MK-ELISA Assay - Colorectal Cancer MK-ELISA Assay - Colorectal Cancer Product Overview MK-ELISA Assay - Esophageal Cancer MK-ELISA Assay - Esophageal Cancer Product Overview MK-ELISA Assay - Gastrointestinal Cancer MK-ELISA Assay - Gastrointestinal Cancer Product Overview MK-ELISA Assay - Metastatic Colorectal Cancer MK-ELISA Assay - Metastatic Colorectal Cancer Product Overview MK-ELISA Assay - Prostate Cancer MK-ELISA Assay - Prostate Cancer Product Overview MK-ELISA Assay - Stromal Cancer MK-ELISA Assay - Stromal Cancer Product Overview MK-ELISA Assay - Thyroid Cancer MK-ELISA Assay - Thyroid Cancer Product Overview Cellmid Ltd - Key Competitors Cellmid Ltd - Key Employees Cellmid Ltd - Locations And Subsidiaries Head Office Other Locations & Subsidiaries Recent Developments Cellmid Ltd, Recent Developments May 30, 2018: 5th Midkine Symposium Reinforces Clinical Potential For Cellmid’S Biotechnology Assets May 29, 2018: Cellmid announces Change of Address Jan 09, 2018: Cellmid Quarterly Operational Update Oct 25, 2017: Cellmid: Notes to the Appendix 4C Oct 16, 2017: Cellmid Appoints Dr Martin Cross as Non-executive Director Sep 27, 2017: Cellmid's FY2017 Results Presentation May 26, 2016: Cellmid provides update on Japanese sale May 09, 2016: Significant Scientific Appointment for Cellmid Advisory Board Chair Apr 08, 2016: Cellmid: Midkine Strategy Update Feb 25, 2016: Interim Financial Report For the Half-Year Ended 31 December 2015 : Cellmid - Appendix
Methodology About GlobalData Contact Us Disclaimer - List of Tables
- Cellmid Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Cellmid Ltd Pipeline Products by Equipment Type
- Cellmid Ltd Pipeline Products by Indication
- Cellmid Ltd, Key Facts
- Cellmid Ltd, Major Products and Services
- Cellmid Ltd Number of Pipeline Products by Development Stage
- Cellmid Ltd Pipeline Products Summary by Development Stage
- CK3000 Cancer Screening Test - Product Status
- CK3000 Cancer Screening Test - Product Description
- Companion Diagnostic Assay - Glioblastoma - Product Status
- Companion Diagnostic Assay - Glioblastoma - Product Description
- CS5000 Cancer Screening Test - Product Status
- CS5000 Cancer Screening Test - Product Description
- MK Protein - Cancer - Product Status
- MK Protein - Cancer - Product Description
- MK-ELISA Assay - Bile Duct Cancer - Product Status
- MK-ELISA Assay - Bile Duct Cancer - Product Description
- MK-ELISA Assay - Colorectal Cancer - Product Status
- MK-ELISA Assay - Colorectal Cancer - Product Description
- MK-ELISA Assay - Esophageal Cancer - Product Status
- MK-ELISA Assay - Esophageal Cancer - Product Description
- MK-ELISA Assay - Gastrointestinal Cancer - Product Status
- MK-ELISA Assay - Gastrointestinal Cancer - Product Description
- MK-ELISA Assay - Metastatic Colorectal Cancer - Product Status
- MK-ELISA Assay - Metastatic Colorectal Cancer - Product Description
- MK-ELISA Assay - Prostate Cancer - Product Status
- MK-ELISA Assay - Prostate Cancer - Product Description
- MK-ELISA Assay - Stromal Cancer - Product Status
- MK-ELISA Assay - Stromal Cancer - Product Description
- MK-ELISA Assay - Thyroid Cancer - Product Status
- MK-ELISA Assay - Thyroid Cancer - Product Description
- Cellmid Ltd, Key Employees
- Cellmid Ltd, Subsidiaries
- Glossary
- List of Figures
- Cellmid Ltd Pipeline Products by Equipment Type
- Cellmid Ltd Pipeline Products by Development Stage